nach oben

Erschienen in:

04.02.2020 | Breast Oncology

Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review

verfasst von: Matthew Castelo, MD, Shu Yang Hu, BSc, MHS, Fahima Dossa, MD, Sergio A. Acuna, MD, PhD, Adena S. Scheer, MD, MSc

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Several randomized controlled trials (RCTs) have investigated observation or axillary radiotherapy (ART) in place of completion axillary lymph node dissection (cALND) for management of positive sentinel nodes (SNs) in clinically node-negative women with breast cancer. The optimal treatment strategy for this population is not known.

Methods

MEDLINE, Embase, and EBM Reviews—NHS Economic Evaluation Database were searched from inception until July 2019. A systematic review and narrative summary was performed of RCTs comparing observation or ART versus cALND in clinically node-negative female breast cancer patients with positive SNs. The Cochrane risk of bias tool for RCTs was used to assess risk of bias. Outcomes of interest included overall survival (OS), disease-free survival (DFS), axillary recurrence, and axillary surgery-related morbidity.

Results

Three trials compared observation with cALND, and two trials compared ART with cALND. No studies blinded participants or personnel, and there was heterogeneity in inclusion criteria, study design, and follow-up. Neither observation nor ART resulted in statistically inferior 5- or 8-year OS or DFS compared with cALND. There was also no statistically significant increase in axillary recurrences associated with either approach. Four trials reported morbidity outcomes, and all showed cALND was associated with significantly more lymphedema, paresthesia, and shoulder dysfunction compared with observation or ART.

Conclusions

Women with clinically node-negative breast cancer and positive SNs can safely be managed without cALND.

Nur mit Berechtigung zugänglich

Klein S. Evaluation of palpable breast masses. Am Fam Physician. 2005;71(9):1731–1738.PubMed

Gradishar WJ, Anderson BO, Abraham J. NCCN Guidelines. Breast Cancer. 2019:215:9–11.

Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(5):561–564. https://doi.org/10.1200/jco.2016.71.0947 CrossRef

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391–398; (discussion 398–401).

Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(30):7703–7720. https://doi.org/10.1200/jco.2005.08.001 CrossRef

Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609. https://doi.org/10.1093/jnci/djj158 CrossRefPubMed

Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–933. https://doi.org/10.1016/s1470-2045(10)70207-2 CrossRefPubMedPubMedCentral

Fisher ER, Redmond C, Fisher B. A perspective concerning the relation of duration of symptoms to treatment failure in patients with breast cancer. Cancer. 1977;40(6):3160–3167.CrossRef

Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–575.CrossRef

10.

Black DM, Mittendorf EA. Landmark trials affecting the surgical management of invasive breast cancer. Surg Clin North Am. 2013;93(2):501–518. https://doi.org/10.1016/j.suc.2012.12.007 CrossRefPubMedPubMedCentral

11.

Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–575. https://doi.org/10.1001/jama.2011.90 CrossRefPubMedPubMedCentral

12.

Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310. https://doi.org/10.1016/s1470-2045(14)70460-7 CrossRefPubMedPubMedCentral

13.

Sávolt Á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: The optimal treatment of the axilla—surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2017;43(4):672–679. https://doi.org/10.1016/j.ejso.2016.12.011 CrossRef

14.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRefPubMed

15.

Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009;62(9):944–952. https://doi.org/10.1016/j.jclinepi.2008.10.012 CrossRefPubMed

16.

Covidence—Better systematic review management. https://www.covidence.org/home. Accessed 14 March 2019.

17.

Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRef

18.

Treadwell J, Uhl S, Tipton K, et al. Assessing Equivalence and Noninferiority. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. http://www.ncbi.nlm.nih.gov/books/NBK98979/. Accessed 30 July 2019.

19.

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.CrossRef

20.

7.7.7.2 Standard errors from confidence intervals and P values: difference measures. https://handbook-5-1.cochrane.org/chapter_7/7_7_7_2_obtaining_standard_errors_from_confidence_intervals_and.htm. Accessed 28 June 2019.

21.

Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–432 https://doi.org/10.1097/sla.0b013e3181f08f32. (discussion 432–433)

22.

Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264(3):413–420. https://doi.org/10.1097/sla.0000000000001863 CrossRefPubMedPubMedCentral

23.

Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–926. https://doi.org/10.1001/jama.2017.11470 CrossRefPubMedPubMedCentral

24.

Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305. https://doi.org/10.1016/s1470-2045(13)70035-4 CrossRefPubMedPubMedCentral

25.

Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018. https://doi.org/10.1016/s1470-2045(18)30380-2 CrossRefPubMed

26.

Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20(1):120–127. https://doi.org/10.1245/s10434-012-2569-y CrossRefPubMed

27.

Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group trial Z0011. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(24):3657–3663. https://doi.org/10.1200/jco.2006.07.4062 CrossRef

28.

Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(32):3600–3606. https://doi.org/10.1200/jco.2014.56.5838 CrossRef

29.

Torgerson DJ, Roland M. What is Zelen’s design? BMJ. 1998;316(7131):606. https://doi.org/10.1136/bmj.316.7131.606 CrossRefPubMedPubMedCentral

30.

van der Velden JM, Verkooijen HM, Young-Afat DA, et al. The cohort multiple randomized controlled trial design: a valid and efficient alternative to pragmatic trials? Int J Epidemiol. 2017;46(1):96–102. https://doi.org/10.1093/ije/dyw050 CrossRefPubMed

31.

Cochrane Handbook for Systematic Reviews of Interventions. http://handbook-5-1.cochrane.org/. Accessed 28 Jan 2019.

32.

Nardone L, Palazzoni G, D’Angelo E, et al. Impact of dose and volume on lymphedema. Rays. 2005;30(2):149–155.PubMed

33.

Bentzen SM, Dische S. Morbidity related to axillary irradiation in the treatment of breast cancer. Acta Oncol Stockh Swed. 2000;39(3):337–347.CrossRef

34.

Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–316.CrossRef

35.

Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–327. https://doi.org/10.1056/nejmoa1415369 CrossRefPubMed

36.

Hennequin C, Bossard N, Servagi-Vernat S, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86(5):860–866. https://doi.org/10.1016/j.ijrobp.2013.03.021 CrossRefPubMed

37.

Budach W, Bölke E, Kammers K, Gerber PA, Nestle-Krämling C, Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiat Oncol Lond Engl. 2015;10:258. https://doi.org/10.1186/s13014-015-0568-4 CrossRef

38.

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03488693. Accessed 26 Dec 2019.

39.

Ozcan LC, Giuliano AE. Is axillary lymph node dissection necessary after a positive sentinel lymph node biopsy? Adv Surg. 2017;51(1):165–178. https://doi.org/10.1016/j.yasu.2017.03.013 CrossRefPubMed

40.

Glechner A, Wöckel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer Oxf Engl 1990. 2013;49(4):812–825. https://doi.org/10.1016/j.ejca.2012.09.010

41.

Huang T-W, Kuo KN, Chen K-H, et al. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system. Int J Surg Lond Engl. 2016;34:73–80. https://doi.org/10.1016/j.ijsu.2016.08.022 CrossRef

42.

Schmidt-Hansen M, Bromham N, Hasler E, Reed MW. Axillary surgery in women with sentinel node-positive operable breast cancer: a systematic review with meta-analyses. SpringerPlus. 2016;5:85. https://doi.org/10.1186/s40064-016-1712-9 CrossRefPubMedPubMedCentral

43.

Zhao M, Liu W-G, Zhang L, et al. Can axillary radiotherapy replace axillary dissection for patients with positive sentinel nodes? A systematic review and meta-analysis. Chronic Dis Transl Med. 2017;3(1):41–50. https://doi.org/10.1016/j.cdtm.2017.01.005 CrossRefPubMedPubMedCentral

44.

de Boniface J, Frisell J, Andersson Y, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17(1):379. https://doi.org/10.1186/s12885-017-3361-y CrossRefPubMedPubMedCentral

45.

Goyal A, Dodwell D. POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol R Coll Radiol G B. 2015;27(12):692–695. https://doi.org/10.1016/j.clon.2015.07.005 CrossRef

46.

Protocol 14PRT/0519. https://www.thelancet.com/doi/story/10.1016/html.2014.12.08.1563. Accessed January 28, 2019.

47.

Houvenaeghel G, Cohen M, Raro P, et al. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node. BMC Cancer. 2018;18(1):1153. https://doi.org/10.1186/s12885-018-5053-7 CrossRefPubMedPubMedCentral

48.

Houvenaeghel G, Resbeut M, Boher J-M. [Sentinel node invasion: is it necessary to perform axillary lymph node dissection? Randomized trial SERC]. Bull Cancer (Paris). 2014;101(4):358–363. https://doi.org/10.1684/bdc.2014.1916 CrossRef

49.

Tinterri C, Canavese G, Bruzzi P, Dozin B. SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. Breast Edinb Scotl. 2016;30:197–200. https://doi.org/10.1016/j.breast.2016.06.016 CrossRef

50.

Acuna SA, Chesney TR, Amarasekera ST, Baxter NN. Defining non-inferiority margins for quality of surgical resection for rectal cancer: a Delphi consensus study. Ann Surg Oncol. 2018;25(11):3171–3178. https://doi.org/10.1245/s10434-018-6639-7 CrossRefPubMed

51.

Acuna SA, Chesney TR, Ramjist JK, Shah PS, Kennedy ED, Baxter NN. Laparoscopic versus open resection for rectal cancer: a noninferiority meta-analysis of quality of surgical resection outcomes. Ann Surg. 2019;269(5):849–855. https://doi.org/10.1097/sla.0000000000003072 CrossRefPubMed

Titel: Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review
verfasst von: Matthew Castelo, MD
Shu Yang Hu, BSc, MHS
Fahima Dossa, MD
Sergio A. Acuna, MD, PhD
Adena S. Scheer, MD, MSc
Publikationsdatum: 04.02.2020
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 8/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08225-y

Trans-Inferior-Pulmonary-Ligament Single-Direction Thoracoscopic RS9 Segmentectomy: Application of Stem-Branch Method for Tracking Anatomy

Thoracic Oncology

Selection of Patients for Organ Preservation After Chemoradiotherapy: MRI Identifies Poor Responders Who Can Go Straight to Surgery

Colorectal Cancer

ASO Author Reflections: The Role of Primary Tumor Resection in Metastatic Midgut Neuroendocrine Tumor

ASO Author Reflections

Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?

Melanoma

What is the Prognostic Value of a Discordant Radiologic and Pathologic Response in Patients Undergoing Resection of Colorectal Liver Metastases After Preoperative Chemotherapy?

Hepatobiliary Tumors

Barriers and Facilitators to De-Implementation of the Choosing Wisely® Guidelines for Low-Value Breast Cancer Surgery

Breast Oncology

Neu im Fachgebiet Chirurgie

Nur selten ernste Komplikationen bei endoskopischer Sinuschirurgie

19.03.2025
Rhinosinusitis
Nachrichten

Etwa 3% der Menschen mit einer endoskopischen Nasennebenhöhlenoperation entwickeln ausgeprägtes Nasenbluten. Andere Komplikationen, wie Verletzungen des Nervus opticus oder eine Meningitis, treten nur äußerst selten auf, legt eine Registeranalyse nahe.

Hochrisiko-Spinaliom am besten mit der Mohs-Chirurgie entfernen

18.03.2025
Plattenepithelkarzinom der Haut
Nachrichten

Die Mohs-Chirurgie ist zwar mit mehr Aufwand verbunden als die herkömmliche Exzision; für die Versorgung kutaner Hochrisiko-Plattenepithelkarzinome lohnt sich die zeitintensive Technik aber in jedem Fall. Laut einer aktuellen Studie sinkt im Vergleich das Sterberisiko.

Mechanische Herzklappe beschert jüngeren Betroffenen längeres Leben

17.03.2025
Herzklappenersatz
Nachrichten

Patienten und Patientinnen bevorzugen bioprothetische Herzklappen gegenüber mechanischen Klappenprothesen. Diese Wahl könnte sich zumindest für jüngere Patienten nachteilig auswirken: Ihnen bietet eine mechanische Klappe anscheinend einen Überlebensvorteil.

Darmpolyp weg – Peptid-Gel gegen Nachblutungen drauf?

17.03.2025
Darmpolypen
Nachrichten

Das Nachblutungsrisiko nach einer endoskopischen Mukosaresektion von flachen kolorektalen und duodenalen Adenomen war in der deutschen PURPLE-Studie mit einem hämostatischen Gel nicht kleiner als ohne Prophylaxe.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review